title: Endolymphatic Hydrops Reversal following Acetazolamide Therapy: Demonstration with Delayed Intravenous Contrast-Enhanced 3D-FLAIR MRI.
abstract: Endolymphatic hydrops, the primary pathologic alteration in Menière disease, can be visualized by using delayed intravenous contrast-enhanced 3D-FLAIR MR imaging. It is not known whether MR imaging-demonstrable changes of hydrops fluctuate with disease activity or are fixed. We describe the results of baseline and posttreatment MR imaging studies in a group of subjects with Menière disease with hydrops who were treated with acetazolamide. Seven subjects with untreated Menière disease with MR imaging evidence of hydrops had repeat MR imaging during acetazolamide treatment. Symptoms and imaging findings were assessed at each time point. Five subjects showed symptom improvement, of whom 3 had improvement or resolution of hydrops. One subject had recurrent symptoms with recurrent hydrops after discontinuing therapy. Two had unchanged hydrops despite symptom improvement. Subjects with unchanged symptoms had unchanged hydrops. Hydrops reversal may be seen with acetazolamide treatment in Menière disease. MR imaging may provide an additional biomarker of disease.
authors.affiliation: From the Departments of Radiological Sciences (A.R.S.) alisepahdari@gmail.com.
authors.forename: A R
authors.identifier: http://orcid.org/0000-0002-3806-1728
authors.initials: AR
authors.lastname: Sepahdari
authors.affiliation: Head and Neck Surgery (N.V., A.I.).
authors.forename: N
authors.initials: N
authors.lastname: Vorasubin
authors.affiliation: Neurology (G.I.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
authors.forename: G
authors.initials: G
authors.lastname: Ishiyama
authors.affiliation: Head and Neck Surgery (N.V., A.I.).
authors.forename: A
authors.initials: A
authors.lastname: Ishiyama
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000328:Adult; D003287:Contrast Media / Q000008:administration & dosage*; D018159:Endolymphatic Hydrops / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D019786:Gadolinium DTPA / Q000008:administration & dosage*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D021621:Imaging, Three-Dimensional / Q000379:methods*; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008575:Meniere Disease / Q000175:diagnosis*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C090600:gadobutrol; D019786:Gadolinium DTPA; D000086:Acetazolamide